1,226 件 ・ 関連度順
概要と使いどころ
Embedded firmware setup: STM32, ESP32, AVR, RP2040, Nordic nRF, Zephyr/RTOS, vendor SDKs, CMake/CMakePresets, VS Code/clangd, cross toolchains, flash/debug, Docker/CI. Use for MCU scaffolds, existing firmware modernization, BSPs, linker/startup files, SDK package selection, and embedded CI; prefer cpp-project-setup for host-side C++.
日本語の概要は準備中です。原文の説明を表示しています。
Take an agent-written app from repo to live production on the user's OWN accounts, with providers they choose (hosting, database, auth, payments, email, domain/DNS). The human connects accounts and approves changes; supported wiring operations run through a local CLI and produce verification evidence with explicit limits. Use when the user wants to ship, deploy, go live, launch, publish, or put their app online, or asks to wire up env vars, webhooks, auth settings (signup, email confirmation, password policy), a real signup → confirmation email → login journey, password recovery, account isolation between two users, auth redirects, email DNS or a custom domain.
日本語の概要は準備中です。原文の説明を表示しています。
Use immediately after RBR confirms a root cause and a fix is scoped, before considering the finding complete. Checks whether the confirmed defect is one instance of a structurally identical pattern elsewhere in the same file family, workflow, or business-domain area, and folds in or explicitly defers every other instance found. Mandatory for Architect and CAO — not an optional lens the agent judges when to apply.
日本語の概要は準備中です。原文の説明を表示しています。
Implements multiplicity control for confirmatory clinical trials using graphical procedures (Bretz-Maurer-Hommel), gatekeeping (parallel, serial, mixed), Hochberg/Hommel/Holm with PRDS, and the closed-testing principle (Marcus-Peritz-Gabriel; Goeman 2021 admissibility). Covers FDA Multiple Endpoints Final Guidance (October 2022), graphical procedures via R gMCP, primary + key-secondary + subgroup hierarchies, and FWER vs FDR distinction. Use when designing the multiplicity strategy for confirmatory trials with multiple primary or key secondary endpoints.
日本語の概要は準備中です。原文の説明を表示しています。
Controls error rates across thousands of simultaneous tests in genomics discovery using false-discovery-rate methods (Benjamini-Hochberg 1995; Benjamini-Yekutieli 2001 for arbitrary dependence; Storey q-value with pi0 estimation; local FDR; independent filtering Bourgon 2010; covariate-weighted FDR via IHW Ignatiadis 2016), plus family-wise error control (Bonferroni, Holm) and the GWAS genome-wide threshold. Covers the FDR-versus-FWER choice as the discovery-versus-confirmatory distinction, the dependence assumptions behind BH (PRDS) versus BY, pi0 estimation, the independent-filtering and false-coverage-rate traps, and reproducibility ranking via IDR (Li 2011). Use when correcting p-values from genome-wide tests, choosing between BH/BY/q-value/Bonferroni, setting an FDR threshold, applying IHW or independent filtering, or interpreting q-values. For confirmatory trials with few pre-specified endpoints (closed testing, graphical/gatekeeping), see clinical-biostatistics/multiplicity-graphical.
日本語の概要は準備中です。原文の説明を表示しています。
Extract line items and delivery details from a customer purchase order PDF, then generate a formatted order confirmation PDF ready to send back to the buyer.
日本語の概要は準備中です。原文の説明を表示しています。
ZMK Firmware (オープンソースキーボードファームウェア) リファレンス。 Getting Started (hardware, user-setup, customization, zmk-cli)、 Features (bluetooth, split keyboards, encoders, displays, lighting, pointing, studio, low-power)、 Keymaps (keycodes, modifiers, combos, conditional layers)、 Behaviors (タップ・ホールド、レイヤー、マクロ、tap-dance, sticky-key)、 Input Processors、Hardware Integration、Troubleshooting (building, flashing, connection, hardware issues)。
Plan the first months at a new Japanese employer after an offer is accepted, listing every expectation and promise made in interviews, the offer, or negotiation with its source, separating what is in writing from what was only said and what has no agreed measure, working out when the probation period ends and whether its criteria and conditions are known, and scheduling who to confirm what with before and after the start date. Use when a user has accepted an offer and wants to prepare for joining, make sure verbal promises such as remote days or a future role are confirmed, or understand what the probation period means for them; do not use to predict whether they will fit in or pass probation, to judge their manager or colleagues, to rule on the legality of probation terms, or to contact the new employer.
日本語の概要は準備中です。原文の説明を表示しています。
Check the working conditions of a Japanese job offer item by item against the conditions an employer states in writing, compare the offer letter or 労働条件通知書 with the job posting and what was said in interviews, and separate what is confirmed in writing from what is still only verbal. Use when a user has received an offer, a working-conditions notice, or an employment contract and wants to know what is missing, what conflicts with earlier statements, and what to confirm before the acceptance deadline; do not use to rule on whether the terms are lawful, to decide whether to accept or decline, or to contact the employer on the user's behalf.
日本語の概要は準備中です。原文の説明を表示しています。
Calls m6A peaks from MeRIP-seq / m6A-seq paired IP-vs-input data using exomePeak2 (transcript-aware, GC-bias-corrected Poisson GLM; Liu 2022 *NAR Genom Bioinform* 4:lqac046), MeTPeak (HMM over sliding windows; Cui 2016 *Bioinformatics* 32:i378), MACS3 / MACS2 with --nomodel --broad --keep-dup all (genome-wide broad alternative), and DRACH motif enrichment confirmation via HOMER or ggseqlogo as a sanity check (NOT a filter). Covers BED12 vs narrowPeak output formats, exonic vs intronic peak handling, multi-tool reconciliation (intersection vs union; cross-caller IDR-equivalent), the m6A-vs-m6Am ambiguity at 5'UTR peaks that antibody-based methods cannot resolve, and orthogonal-validation routes (miCLIP / GLORI / m6A-SAC-seq / m6Anet). Use when calling peaks from paired IP/input genome BAMs, choosing exomePeak2 (transcript-aware default) vs MACS3 (broad genomic) vs MeTPeak (HMM-smoothed low-coverage), confirming DRACH enrichment as a sanity check on the peak set as a whole, reconciling differing peak sets across tools, validating MeRIP peaks against orthogonal single-base methods, interpreting peaks at the 5' end where m6Am contamination is possible, or recommending a multi-tool consensus strategy.
日本語の概要は準備中です。原文の説明を表示しています。
Controls error rates across thousands of simultaneous tests in genomics discovery using false-discovery-rate methods (Benjamini-Hochberg 1995; Benjamini-Yekutieli 2001 for arbitrary dependence; Storey q-value with pi0 estimation; local FDR; independent filtering Bourgon 2010; covariate-weighted FDR via IHW Ignatiadis 2016), plus family-wise error control (Bonferroni, Holm) and the GWAS genome-wide threshold. Covers the FDR-versus-FWER choice as the discovery-versus-confirmatory distinction, the dependence assumptions behind BH (PRDS) versus BY, pi0 estimation, the independent-filtering and false-coverage-rate traps, and reproducibility ranking via IDR (Li 2011). Use when correcting p-values from genome-wide tests, choosing between BH/BY/q-value/Bonferroni, setting an FDR threshold, applying IHW or independent filtering, or interpreting q-values. For confirmatory trials with few pre-specified endpoints (closed testing, graphical/gatekeeping), see clinical-biostatistics/multiplicity-graphical.
日本語の概要は準備中です。原文の説明を表示しています。
Implements multiplicity control for confirmatory clinical trials using graphical procedures (Bretz-Maurer-Hommel), gatekeeping (parallel, serial, mixed), Hochberg/Hommel/Holm with PRDS, and the closed-testing principle (Marcus-Peritz-Gabriel; Goeman 2021 admissibility). Covers FDA Multiple Endpoints Final Guidance (October 2022), graphical procedures via R gMCP, primary + key-secondary + subgroup hierarchies, and FWER vs FDR distinction. Use when designing the multiplicity strategy for confirmatory trials with multiple primary or key secondary endpoints.
日本語の概要は準備中です。原文の説明を表示しています。
Calls m6A peaks from MeRIP-seq / m6A-seq paired IP-vs-input data using exomePeak2 (transcript-aware, GC-bias-corrected Poisson GLM; Liu 2022 *NAR Genom Bioinform* 4:lqac046), MeTPeak (HMM over sliding windows; Cui 2016 *Bioinformatics* 32:i378), MACS3 / MACS2 with --nomodel --broad --keep-dup all (genome-wide broad alternative), and DRACH motif enrichment confirmation via HOMER or ggseqlogo as a sanity check (NOT a filter). Covers BED12 vs narrowPeak output formats, exonic vs intronic peak handling, multi-tool reconciliation (intersection vs union; cross-caller IDR-equivalent), the m6A-vs-m6Am ambiguity at 5'UTR peaks that antibody-based methods cannot resolve, and orthogonal-validation routes (miCLIP / GLORI / m6A-SAC-seq / m6Anet). Use when calling peaks from paired IP/input genome BAMs, choosing exomePeak2 (transcript-aware default) vs MACS3 (broad genomic) vs MeTPeak (HMM-smoothed low-coverage), confirming DRACH enrichment as a sanity check on the peak set as a whole, reconciling differing peak sets across tools, validating MeRIP peaks against orthogonal single-base methods, interpreting peaks at the 5' end where m6Am contamination is possible, or recommending a multi-tool consensus strategy.
日本語の概要は準備中です。原文の説明を表示しています。
Controls error rates across thousands of simultaneous tests in genomics discovery using false-discovery-rate methods (Benjamini-Hochberg 1995; Benjamini-Yekutieli 2001 for arbitrary dependence; Storey q-value with pi0 estimation; local FDR; independent filtering Bourgon 2010; covariate-weighted FDR via IHW Ignatiadis 2016), plus family-wise error control (Bonferroni, Holm) and the GWAS genome-wide threshold. Covers the FDR-versus-FWER choice as the discovery-versus-confirmatory distinction, the dependence assumptions behind BH (PRDS) versus BY, pi0 estimation, the independent-filtering and false-coverage-rate traps, and reproducibility ranking via IDR (Li 2011). Use when correcting p-values from genome-wide tests, choosing between BH/BY/q-value/Bonferroni, setting an FDR threshold, applying IHW or independent filtering, or interpreting q-values. For confirmatory trials with few pre-specified endpoints (closed testing, graphical/gatekeeping), see clinical-biostatistics/multiplicity-graphical.
日本語の概要は準備中です。原文の説明を表示しています。
Implements multiplicity control for confirmatory clinical trials using graphical procedures (Bretz-Maurer-Hommel), gatekeeping (parallel, serial, mixed), Hochberg/Hommel/Holm with PRDS, and the closed-testing principle (Marcus-Peritz-Gabriel; Goeman 2021 admissibility). Covers FDA Multiple Endpoints Final Guidance (October 2022), graphical procedures via R gMCP, primary + key-secondary + subgroup hierarchies, and FWER vs FDR distinction. Use when designing the multiplicity strategy for confirmatory trials with multiple primary or key secondary endpoints.
日本語の概要は準備中です。原文の説明を表示しています。
This skill should be used when the user asks to "PR を出す前に確認して", "check if this branch is ready to merge", "run pre-PR checks", "PRを作る前にチェックして", or wants to verify a branch before opening a pull request. Executes verification commands, validates Conventional Commits format, and confirms documentation is updated, then reports whether gh pr create is safe to run.
Replicate and validate a GitHub issue by spinning up Archon, analyzing the issue, and systematically testing all described symptoms using browser automation. Use when: User wants to reproduce a bug, validate a GitHub issue, confirm a reported problem, or investigate whether an issue is real before working on a fix. Triggers: "replicate issue", "reproduce issue", "validate issue", "confirm bug", "test issue", "can you reproduce", "try to replicate", "verify the bug". Capability: Checks out main, pulls latest, starts Archon, reads the GitHub issue, then uses agent-browser to systematically test every symptom and produce a findings report. NOT for: Fixing issues (use /archon or /exp-piv-loop:fix-issue), general UI testing (use /validate-ui).
日本語の概要は準備中です。原文の説明を表示しています。
Use when confirming whether a dispatched agent task was actually received, activated, and progressing after sessions_send or other task handoff actions.
日本語の概要は準備中です。原文の説明を表示しています。
Research venture capital firms, angel investors, and funding sources for startup fundraising. Use when: "投资人调研", "找VC", "research investors", "VC list", "funding sources", "investor database", "天使投资人", "venture capital", "融资对象", "投资人画像". Generates a structured investor research report with firm profiles, investment thesis, portfolio companies, contact strategies, and warm introduction paths. Part of UniqueClub founder toolkit. Learn more: https://uniqueclub.ai Pairs with pitch-deck-creator for complete fundraising preparation.
日本語の概要は準備中です。原文の説明を表示しています。
Pyramid multi-agent orchestration for OpenClaw: routes objectives from a CEO agent down through departments, services and employees via sessions_send / sessions_spawn, collects and merges results, enforces handoff contracts, and writes the final deliverable back to the originating session.
日本語の概要は準備中です。原文の説明を表示しています。
IoT and embedded device security testing methodology. Covers hardware reconnaissance (UART, JTAG, SWD, SPI flash, I2C EEPROM, eMMC chip-off), firmware acquisition (vendor portals, OTA capture, flash dump, binwalk extraction), firmware analysis (filesystem mounting, binary triage, hardcoded secrets, default credential discovery), bootloader attacks (U-Boot console, secure-boot bypass, fault injection), runtime attacks on embedded Linux/RTOS (busybox CVEs, MTD writes, /dev/mem), wireless protocol attacks (Zigbee, BLE, Z-Wave, LoRaWAN, Thread/Matter, sub-GHz), MQTT/CoAP/Modbus/BACnet/OPC-UA exploitation, mobile companion app analysis, cloud-IoT API abuse, and side-channel/glitching basics. Use for IoT pentest, smart-home assessment, ICS/OT testing, or embedded vulnerability research.
日本語の概要は準備中です。原文の説明を表示しています。
Methodology for detecting client SOC patches, attacker activity, and security-state changes that occur DURING a red-team engagement — and converting those observations into deliverable findings. Built from authorized red-team work where the client patched a confirmed SQLi within 30 minutes of detection AND an external attacker locked multiple new accounts during a single test session. Use when (a) running ANY active engagement against a monitored target, (b) a previously-confirmed finding stops reproducing, (c) baseline timing shifts unexpectedly, or (d) you notice response patterns changing during testing.
日本語の概要は準備中です。原文の説明を表示しています。
Enriches inbound leads with firmographic and technographic data. Takes minimal lead info and enriches via WebSearch, Apollo, or ZoomInfo to produce a complete lead record with company size, revenue, tech stack, social profiles, and decision-maker details.
日本語の概要は準備中です。原文の説明を表示しています。
新規・既存テストが守る動作と不具合を確かめ、重複や実装への依存を見直すスキル。削除の根拠を整理し、必要な検証を残してテスト用コードも整理します。